Stuart L. Schreiber
- Molecular Biology top 5%
- Oncology top 5%
- Immunology top 5%
- Organic Chemistry top 10%
- Cell Biology top 10%
- Co-authors
- Andrzej GałatMatthew W. HardingDavid UehlingRobert F. StandaertGregory L. VerdineGerald R. CrabtreeDavid FiorentinoXiao-Feng Zheng
- Topics
- Signaling Pathways in Disease (4 papers)Peptidase Inhibition and Analysis (3 papers)Innovative Microfluidic and Catalytic Techniques Innovation (2 papers)
- Cited by
- Molecular BiologyImmunologyOncology
- Journals
- NatureCellGastroenterology
- Partner nations
- United StatesJapanSouth Korea
In The Last Decade
Stuart L. Schreiber
12 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Molecular Biology 2.3k
- Oncology 638
- Immunology 615
- Organic Chemistry 320
- Cell Biology 154
Countries citing papers authored by Stuart L. Schreiber
This map shows the geographic impact of Stuart L. Schreiber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart L. Schreiber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart L. Schreiber more than expected).
Fields of papers citing papers by Stuart L. Schreiber
This network shows the impact of papers produced by Stuart L. Schreiber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart L. Schreiber. The network helps show where Stuart L. Schreiber may publish in the future.
Co-authorship network of co-authors of Stuart L. Schreiber
This figure shows the co-authorship network connecting the top 25 collaborators of Stuart L. Schreiber. A scholar is included among the top collaborators of Stuart L. Schreiber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart L. Schreiber. Stuart L. Schreiber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 70 | |
| 2 | 214 | |
| 3 | 60 | |
| 4 | 52 | |
| 5 | 75 | |
| 6 | 63 | |
| 7 | 243 | |
| 8 | 70 | |
| 9 | 300 | |
| 10 | 107 | |
| 11 | 279 | |
| 12 | A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomerasebreakdown → | 1154 |
About Stuart L. Schreiber
Stuart L. Schreiber is a scholar working on Oncology, Molecular Biology and Hepatology, having authored 12 papers that have together received 2.7k indexed citations. Recurring topics across this work include Signaling Pathways in Disease (4 papers), Peptidase Inhibition and Analysis (3 papers) and Innovative Microfluidic and Catalytic Techniques Innovation (2 papers). The work is most often cited by research in Molecular Biology (2.3k citations), Immunology (615 citations) and Oncology (638 citations). Stuart L. Schreiber has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Andrzej Gałat, Matthew W. Harding, David Uehling, Robert F. Standaert, Gregory L. Verdine, Gerald R. Crabtree, David Fiorentino, Xiao-Feng Zheng, Jie Chen and Julian A. Simon. Their work appears in journals such as Nature, Cell and Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.